Cargando…
Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598311/ https://www.ncbi.nlm.nih.gov/pubmed/37886193 http://dx.doi.org/10.21037/hbsn-23-342 |
| _version_ | 1785125526245998592 |
|---|---|
| author | Yoneda, Masato Kobayashi, Takashi Wada, Naohiro Otani, Tomohiro Nogami, Asako Iwaki, Michihiro Nakajima, Atsushi |
| author_facet | Yoneda, Masato Kobayashi, Takashi Wada, Naohiro Otani, Tomohiro Nogami, Asako Iwaki, Michihiro Nakajima, Atsushi |
| author_sort | Yoneda, Masato |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10598311 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105983112023-10-26 Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved Yoneda, Masato Kobayashi, Takashi Wada, Naohiro Otani, Tomohiro Nogami, Asako Iwaki, Michihiro Nakajima, Atsushi Hepatobiliary Surg Nutr Editorial Commentary AME Publishing Company 2023-09-04 2023-10-01 /pmc/articles/PMC10598311/ /pubmed/37886193 http://dx.doi.org/10.21037/hbsn-23-342 Text en 2023 Hepatobiliary Surgery and Nutrition. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Yoneda, Masato Kobayashi, Takashi Wada, Naohiro Otani, Tomohiro Nogami, Asako Iwaki, Michihiro Nakajima, Atsushi Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title | Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title_full | Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title_fullStr | Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title_full_unstemmed | Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title_short | Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| title_sort | tropifexor, a selective non-acid farnesoid x receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598311/ https://www.ncbi.nlm.nih.gov/pubmed/37886193 http://dx.doi.org/10.21037/hbsn-23-342 |
| work_keys_str_mv | AT yonedamasato tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT kobayashitakashi tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT wadanaohiro tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT otanitomohiro tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT nogamiasako tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT iwakimichihiro tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved AT nakajimaatsushi tropifexoraselectivenonacidfarnesoidxreceptoragonistimprovednonalcoholicsteatohepatitisinaphase2trialbutseveralissuesremaintoberesolved |